LLY

1,062.33

+2.23%↑

JNJ

234.65

+2.2%↑

ABBV

216.6

+1.16%↑

UNH

388.46

+0.99%↑

AZN

187.64

-0.52%↓

LLY

1,062.33

+2.23%↑

JNJ

234.65

+2.2%↑

ABBV

216.6

+1.16%↑

UNH

388.46

+0.99%↑

AZN

187.64

-0.52%↓

LLY

1,062.33

+2.23%↑

JNJ

234.65

+2.2%↑

ABBV

216.6

+1.16%↑

UNH

388.46

+0.99%↑

AZN

187.64

-0.52%↓

LLY

1,062.33

+2.23%↑

JNJ

234.65

+2.2%↑

ABBV

216.6

+1.16%↑

UNH

388.46

+0.99%↑

AZN

187.64

-0.52%↓

LLY

1,062.33

+2.23%↑

JNJ

234.65

+2.2%↑

ABBV

216.6

+1.16%↑

UNH

388.46

+0.99%↑

AZN

187.64

-0.52%↓

Home・Lista de Ações・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Abrir

SetorSaúde

30.82 1.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

30.37

Máximo

31.16

Indicadores-chave
By Trading Economics
Rendimento	2.6M -79M
Vendas	-60K 15K
EPS	-1.18
Margem de lucro	-524,566.667
Funcionários	198
EBITDA	-3M -84M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+85.51% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-200M 2.4B
Abertura anterior	29.64
Fecho anterior	30.82

Sentimento de Notícias

By Acuity

50%

148 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

18.91 / 20.63 Suporte e Resistência

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de mai. de 2026, 22:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 de mai. de 2026, 16:49 UTC

Ganhos

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 de mai. de 2026, 16:26 UTC

Grandes Movimentos do Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 de mai. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 de mai. de 2026, 23:37 UTC

Ganhos

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

21 de mai. de 2026, 23:30 UTC

Conversa de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 de mai. de 2026, 22:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Conduent to Sell Public Transit Business to Modaxo for $164M

21 de mai. de 2026, 21:53 UTC

Ganhos

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 de mai. de 2026, 21:02 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 de mai. de 2026, 20:55 UTC

Ganhos

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 de mai. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 de mai. de 2026, 20:20 UTC

Conversa de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Adj EPS 3c >BULL

21 de mai. de 2026, 20:20 UTC

Ganhos

Webull 1Q Rev $159.9M >BULL

21 de mai. de 2026, 20:18 UTC

Conversa de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 de mai. de 2026, 20:18 UTC

Ganhos

Webull 1Q Loss/Shr 4c

21 de mai. de 2026, 19:43 UTC

Conversa de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 de mai. de 2026, 18:58 UTC

Ganhos

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 de mai. de 2026, 18:15 UTC

Conversa de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 de mai. de 2026, 17:40 UTC

Conversa de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 de mai. de 2026, 17:04 UTC

Conversa de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 de mai. de 2026, 17:01 UTC

Ganhos

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Ganhos

Stellantis Targets Distant but Constructive -- Market Talk

21 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

85.51% parte superior

Previsão para 12 meses

Média 56.73 USD 85.51%

Máximo 90 USD

Mínimo 38 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

148 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.